Skip to main content
Figure 3 | BMC Pharmacology and Toxicology

Figure 3

From: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®

Figure 3

Mean neutrophile counts (× 10 9 /l) ± SD obtained in groups of 10 neutropenic rats treated for 4 days by subcutaneous injections of 10, 30 and 100 μg/kg/day of BK0023 and Neupogen ®  are respectively shown in left, central and right panels where full circles, squares and triangles are respectively referred to control rats, BK0023 and Neupogen. No significant difference was found between BK0023 and Neupogen treated groups analysed by Student’s test. Significant differences between treated and control groups analysed by Dunnet’s test were found at P < 0.05 (*) or P < 0.01 (**).

Back to article page